Through binding to PD-1, nivolumab prevents tumor cells from neutralizing T cell responses, thereby enhancing host T cell proliferation, increasing cytokine production, and leading to anti-tumor immune response [27]. This evidence concerns the gene PDCD1 and neoplasm.